New data on the safety of IV iron - But why the discrepancy with FIND-CKD?

Kidney International

Volumn 88, Issue 6, 2015, Pages 1445-1446

  Macdougall, Iain C ^a   Roger, Simon D ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b GOSFORD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; IRON;

ADVERSE DRUG REACTION; ANEMIA; CHRONIC KIDNEY DISEASE; DATA ANALYSIS; DRUG SAFETY; FOLLOW UP; HEART DISEASE; HUMAN; INCIDENCE; INFECTION; IRON DEFICIENCY ANEMIA; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 84949779219     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.302     Document Type: Letter

References (2)

1. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88: 905-914
2. Macdougall IC, Bock AH, Carrera F et al.; FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084.